Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial

Juliette Lambert, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Pascal Turlure, Denis Caillot, Olivier Legrand, Xavier Thomas, Claude Gardin, Karin Gogat-Marchant, Stephen D Rubin, Rebecca J Benner, Pierre Bousset, Claude Preudhomme, Sylvie Chevret, Herve Dombret, and Sylvie Castaigne

Disclosures: S.Ca has received grants from Pfizer and personal fees from Pfizer, outside the submitted work. J.L. reports personal fees from Pfizer, outside the submitted work. H.D. reports personal fees and other from Pfizer. K.G-M., S.R., R.J.B., and P.B. are Pfizer Inc. employees and stock owners. No other authors have conflicts of interest to disclose.

Contributions: S.Ca., and S.Ch contributed to conception of the study and/or study design; J.L., S.Ca., C.Pa., C.T., E.R., P.T., D.C., O.L., X.T., C.G., C.Pr., and H.D. contributed to execution of the study; S.Ca., K.G., S.R., R.J.B., and P.B. collected and assembled the data; S.Ca., S.Ch., K.G., S.R., R.J.B., and P.B. contributed to analysis and interpretation of the data; and all authors contributed to writing and/or critical review of the manuscript and approved the final version for submission.